Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib

NCT01289821 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01289821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01289821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
June 30, 2014
Enrollment
54 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms